The global uveitis treatment market reached a value of US$ 1.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.2 Billion by 2027, exhibiting a CAGR of 5.95% during 2022-2027.
Uveitis refers to a condition that causes inflammation of the middle layer of tissue in the eyewall uvea. It causes swelling that can damage the eye tissues, leading to poor vision or blindness. Uveitis is mainly caused by autoimmune diseases in which the body attacks itself, causing inflammation, infection and tumor in the eyes or other parts of the body. The treatment for uveitis involves a therapeutic process that can heal the inflammation of the uvea and surrounding tissues. It is treated with the help of drugs such as cycloplegic agents, anti-inflammatory, antimicrobials, as well as immunotherapy and targeted therapies. Uveitis treatment also provides the patient with relief from the pain, prevents further damage of the tissues, and restores vision loss.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Uveitis Treatment Market Trends:
The market is driven by the increasing prevalence of uveitis and other infectious eye disorders in individuals. Besides this, the growing awareness regarding the need for proper treatment among patients is also encouraging the adoption of advanced therapeutics. In addition to this, the rising complication associated with uveitis has resulted in increased investment in healthcare, thereby fueling the market growth. Furthermore, individualswith diabetes, eye injuries, cataracts, glaucoma, band keratopathy, and inflammatory disorders are more susceptible to uveitis. As a result, governments of different nations are taking initiatives to accelerate the approval of drugs in the pipeline and new routes of drug administration to improve the efficacy of the drugs. In addition to this, there has been a rise in the number of clinical trials for eye inflammation treatments for refractory posterior and intermediate uveitis across the globe. Nowadays, several leading manufacturers have increased their production capacity of the medication. Moreover, extensive research and development (R&D) activities in the field of ophthalmology have led to the introduction ofadvanced uveitis treatment, creating lucrative opportunities in the market
Request Free Sample Report:
Uveitis Treatment Market 2022-2027 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc. and Santen Pharmaceutical Co. Ltd.
The report has segmented the market on the basis on region, Treatment Type, Disease Type, Cause and Distribution Channel.
Breakup by Treatment Type:
- Monoclonal Antibodies
- Cycloplegic Agents
Breakup by Disease Type:
- Anterior Uveitis
- Posterior Uveitis
- Intermediate Uveitis
Breakup by Cause:
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Breakup by Region:
- North America: United States, Canada
- Asia Pacific: China, Japan, India, South Korea, Australia, Indonesia, Others
- Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Others
- Latin America: Brazil, Mexico, Other
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/uveitis-treatment-market
If you want latest primary and secondary data (2022-2027 with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Other Report by IMARC Group:
India Surgical Sutures Market Size: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027
Atherectomy Devices Market Size: Global Industry Trends, Share, Growth, Opportunity and Forecast 2021-2026
Idiopathic Pulmonary Fibrosis Treatment Market Size: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027
Blood Bags Market Report 2021-2026: Industry Trends, Share, Size, Growth, Opportunity and Forecast
Japan Idiopathic Pulmonary Fibrosis Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027
Facial Injectables Market Size: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
Cone Beam Imaging Market Size: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
Eubiotics Market Share: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800